Because plasma kallikrein activates human neutrophils, and in plasma prekallikrein (PK) 
Introduction
High molecular weight kininogen (HMWK)' serves as a cofactor in the activation of the-zymogen plasma kallikrein (PK) (1) . In plasma, PK is a zymogen that circulates in a noncovalent complex with HMWK (2, 3) . The binding of HMWK to negatively charged surfaces enables PK to attach to negatively charged surfaces where the zymogen can be optimally activated to kallikrein by Factor XIIa (4, 5). Kallikrein expresses chemotactic (6) , aggregating (7) , and degranulating (8) activity with neutrophils. Other chemotactic factors for neutrophils such as FMLP (9) and C5a (10), have been shown to have 1. Abbreviations used in this paper: FDNPS, fibrinogen degradation products; HMWK, high molecular weight kininogen; HNE, human neutrophil elastase; PK, prekallikrein. specific binding sites on neutrophils. The receptor(s) for plasma kallikrein on neutrophils is not known.
Although receptors are frequently integral membrane proteins, at least one enzyme Factor Xa binds to a cell (platelet) through an "acquired receptor," the plasma cofactor Factor Va (1 1). We postulated that kallikrein might bind to neutrophils through its cofactor, HMWK, with which it complexes. Platelets have been shown to contain a form of HMWK (12, 13) , which can be expressed on the activated platelet surface (14) . As HMWK has been shown to bind to activated (15) and unstimulated (16) platelets, studies were initiated to determine if neutrophils also contain a form' of HMWK and whether the external membrane of human neutrophils possesses a specific binding site for HMWK. The results ofthis investigation demonstrate that neutrophils contain HMWK and possess a specific, reversible, and saturable binding site for HMWK. Furthermore, HMWK from either plasma or neutrophils is a cofactor for HNE secretion.
Methods
Materials. Iodogen (chloramide, 1,3,4,6-tetrachloro-3 alpha, 6 alphadiphenylglycoluril) was obtained from Pierce Chemical Co., Rockford, IL. '251-Na (50 mCi/mmol) was obtained from ICN Pharmaceuticals, Irvine, CA. N-Butyl-phthalate was obtained from Fisher Scientific Co., Pittsburgh, PA. Apiezion oil (a mixture of silicon oils) was obtained from Apiezion Products Limited, London, England. HBSS free of calcium chloride, magnesium sulfate, and magnesium chloride was obtained from Gibco Laboratories, Grand Island, NY. Ficoll-Hyaque was obtained from Pharmacia Fine Chemicals, Piscataway, NJ.
Plasma and neutrophils. Pooled normal plasma (lot 6130) was purchased from George King Biomedical Inc., Overland Park, KS. Total kininogen-deficient plasma (plasma deficient in both HMWK and low molecular weight kininogen) and neutrophils deficient in HMWK were donated by Mrs. Mayme Williams. Normal donors were young males and females (age 21-45 yr) receiving no medication, who had given their written, informed consent.
Neutrophil isolation. Human neutrophils were isolated from whole blood anticoagulated with one-tenth volume acid-citrate-dextrose by sedimentation at 1 g in dextran (1.5%). After sedimentation, the upper leukocyte-enriched plasma was gently layered over 15 ml of FicollHyaque (each 100 ml contains 5.7 g Ficoll 400 and 9.0 g sodium ditrizoate sodium) and centrifuged at 400 g for 30 min at 230C. The cell pellet was resuspended in an erythrocyte lysis buffer composed of 155 mM NH4C1, 2.7 mM KHCO3, and 3.7 mM EDTA. The suspension was centrifuged at 400 g for 20 min and the cell pellet was washed three times in excess saline, pH 7.4. After the final saline wash, the cells were resuspended in HBSS without magnesium or calcium (1 X 107-109 cells/ml). Cell count and purity were detpmined after dilution in Turk's solution (3% glacial acetic acid and 1% crystal violet). This procedure yielded -8 X 108 neutrophils/unit whole blood and the cells were isolated to 96% purity. The number of platelets per neutrophil averaged 5 per 100 (range 3 to 8). The cells were either solubilized with 0.5% Triton X-100 (final concentration) and stored at -70°C for antigen determination or used immediately in binding experiments.
Proteins. HMWK was purified using a modified method (14) of Kerbiriou and Griffin (17) . Under reducing conditions, this preparation of HMWK appeared on a 7.5% SDS-polyacrylamide gel (18) as primarily a single 120,000-kD band with > 98% purity and a specific activity of 12-20 U/ml. Purified HMWK was radiolabeled with '251-Na using Iodogen by the method of Fraker and Speck (19) under conditions previously described ( 16) . The specific radioactivity of the protein varied from 1-3.5 ACi/g and > 75% of the molecules of HMWK being iodinated. The radiolabeled protein retained > 95% of its procoagulant activity as well as its antigenic properties as previously reported (16) .
Purified Factor XII (70 ,g/ml), PK (1 mg/ml), and aI-antiprotease inhibitor were provided by Dr. Robin Pixley; fibronectin degradation products (FNDPs) (1.3 mg/ml) were donated by Dr. Andrei Budzynski, and Factor V was donated (0.93 mg/ml) by Dr. Angie Annamalai, all of Temple University, Philadelphia, PA. Foy, a specific inhibitor of cathepsin G (20) and a monospecific polyclonal antibody to HNE (21), were generously provided by Dr. Fred Kueppers, Temple University, Philadelphia, PA. Eglin, an inhibitor of cathepsin G and HNE, was generously provided by Dr. Hans-Peter Schnebli, CibaGeigy AG, Basel, Switzerland. HNE was purified to homogeneity by the procedure of Baugh and Travis (22) .
Assays. HMWK procoagulant activity was measured by a onestage kaolin activation assay (23) using total kininogen-deficient plasma as substrate. Samples were compared with a simultaneously performed standard curve from pooled normal human plasma diluted one-tenth to one-thousandth with 0.01 M Tris, 0.15 M NaCI, pH 7.4. One unit was defined as that amount of procoagulant activity in I ml ofpooled normal plasma. HMWK antigen was measured by a competitive ELISA, performed as previously reported (12) using a monospecific polyclonal antibody directed to the 56-kD light chain of HMWK (12) . HNE activity was measured by a chromogenic assay using the substrate, methoxysuccinyl-Ala-Ala-Pro-Val-pNA (24) and antigenic levels were measured using a competitive ELISA specific for HNE (8) . Cathepsin G activity was measured using the spectrophotometric assay described by Barrett (25) . Lactic dehydrogenase loss from washed neutrophils was measured by the procedure of Wroblewski and Ladue (26) .
Neutrophil aggregation. Aggregation wwperformed with modifications ofthe previously described method (74zi-eutrophils (1 X 107/ml) were resuspended in a total volume of 1 nLHBSS containing a final concentration of 2 mM CaCl2, 1.5 mM MgCl2, and 5 jug cytochlasin B in the presence of agonist. Aggregation was measured using a platelet aggregometer (Monitor IV Plus, Helena Laboratories, Beaumont, TX) revolving at 900 rpm.
Neutrophil degranulation in an in vitro plasma-free system. Supernatants were harvested for subsequent HNE activity determinations by centrifuging the contents of the aggregation cuvettes at 13,000 g for 5 min at 23°C in a microcentrifuge (model 235A; Fisher Scientific Co.). The supernatants were assayed using the chromogenic substrate methoxysuccinyl-Ala-Ala-Pro-Val-PNA (8) .
Neutrophil degranulation in an in vitro plasma system. Neutrophils (1 X 107/ml) were resuspended in polypropylene tubes containing plasma whereupon Ca2" (final concentration 30 mM) was added. Incubations were performed for various times at 23°C, and aliquots were then removed and centrifuged at 13,000 g for 5 min at 23°C in a microcentrifuge. The plasma supernatants were stored at -70°C until immunochemical determinations ofelastase were made, using an indirect competitive ELISA (8, 33) .
Binding experiments. In all binding experiments neutrophils were at a final concentration of 1 X 10'/ml. In a typical binding experiment 300-400 Al of washed neutrophils in HBSS without added calcium or magnesium, pH 7.4, were incubated at 23°C, without stirring in a 1.5-ml conical polypropylene centrifuge tube (Sarstedt, Inc., Princeton, NJ) with 125I-HMWK and additions to a total volume of 350-450
Ml were made. After incubation of appropriately expanded volumes, 50-,Ml aliquots were removed (in triplicate) for each experimental point and centrifuged at 9,650 g at 230C in a microfuge (model B; Beckman Instruments, Inc., Fullerton, CA) through a 200-Al mixture of silicon oils (one part Apiezion/nine parts N-butyl-phthalate) in polypropylene microsedimentation tubes with narrow bore extended tips (Sarstedt, Inc., Princeton, NJ) for 2 min. After the supernatant was removed, the tips containing the pellet were amputated and counted in a gamma counter (Rack; LKB Instruments, Inc., Gaithersburg, MD).
Detection ofHMWK on the surface ofwashed neutrophils. Detection ofthe amount of neutrophil HMWK on the surface ofthe neutrophil was performed by a competitive ELISA developed for measuring surface HMWK on platelets (19) and modified for neutrophils. The neutrophil samples were prepared for use in a modified competitive ELISA for HMWK as an indirect antibody consumption assay. Conditions for this antibody consumption assay for surface-expressed neutrophil HMWK were developed so that intraneutrophil HMWK (that which was neither secreted nor expressed on the external membrane) would not interfere. Four samples were prepared: (a) suspension of neutrophils; (b) suspension buffer from pelleted neutrophils; (c) buffer alone (negative control); and (d) buffer containing 200 ng/ml HMWK (positive control). Each specimen was mixed with an equal volume of monospecific anti-HMWK antisera (final concentration 1:500). This antisera had previously been diluted 1:250 in 0.01 mol/liter HBSS and was also made 1:250 with total kininogen deficient plasma. Before the prepared antisera was mixed with the neutrophil material, the antisera was ultracentrifuged at 100,000 g for 90 min in a ultracentrifuge (model L3-50, Beckman Instruments, Inc.) to remove any aggregates that might be present. The total kininogen-deficient plasma was added to the incubation mixture to prevent nonspecific association of goat anti-HMWK IgG to human neutrophil Fc receptors by the addition of excess human IgG. After the four neutrophil samples were combined with the antisera, each mixture was incubated for 1 h at 370C. At completion ofthe incubation, each specimen was centrifuged at 12,000 g in a microcentrifuge, and the supernatants were collected.
Four antibody samples per experiment were then compared by a competitive ELISA assay for HMWK (19) using known amounts of purified HMWK antigen to determine the slope of the competitive inhibition curve produced by each. The competitive inhibition curves generated on the competitive ELISA by the four aliquots of adsorbed antisera were produced by the method of incubation of samples as previously reported (19) . However, because the aim ofthe assay was to determine whether the titer of the antisera would be decreased (consumed) by incubation with neutrophils or their supernatants, the final competitive inhibition curves were analyzed by linear regression to determine the slope of the competitive inhibition curve produced by antisera adsorbed with each of the aliquots of neutrophil material. In all experiments, the differently adsorbed aliquots of antisera were reacted with the same amounts of purified HMWK (1-125 ng). The measured value ofthis assay was the slope ofthe competitive inhibition curve.
Statistical analysis. Calculation of bound HMWK was based on the specific activities of the radiolabeled ligand, and the results were expressed as nanograms of HMWK per 107 neutrophils. In a typical experiment, total binding was the amount of 1251-HMWK bound in the absence ofunlabeled ligand, while nonspecific binding was the amount of '25I-HMWK bound in the presence of a 50-fold molar excess of unlabeled ligand. Specific binding was obtained by subtracting the nonspecific binding from the total binding.
In competition inhibition experiments with unlabeled HMWK, the affinity ofbinding of '25l-HMWK was calculated from the IC50 (27) as previously reported (16, 28) using a computer program to determine the 50% inhibition point (29) . In concentration-dependent experiments, binding '25I-HMWK to PMNs was also analyzed by the graphical methods of Scatchard (30) (31) . After calculating the amount of specifically bound ligand the data were also fit by the program developed by Brass (32) .
Comparison of the differences of experimental groups in the binding studies were performed by the t test (paired). Significant differences are defined as P < 0.05. All values are expressed as mean±SEM.
Results
Identification of neutrophil HMWK. To delineate how HMWK may interact with neutrophils, studies were first performed to determine if washed human neutrophils contain associated HMWK antigen (Fig. 1) . Washed solubilized neutrophils from normal blood donors were found to have 237±61 ng HMWK antigen/108 cells (mean±SEM, n = 8). This result was specific for the identification of HMWK antigen because a lysate of neutrophils from a patient with a known total deficiency ofplasma and platelet HMWK (12, 23) had a neutrophil HMWK value of . 2.7 ng/108 cells (Fig, 1) . Neutrophil HMWK was immunochemically identical to plasma HMWK, as indicated by parallel competition inhibition curves produced on a competitive ELISA (data not shown).
Detection ofHMWK on the surface ofwashed neutrophils. Neutrophils, their supernatants, and controls were incubated with antiserum directed against the light chain of HMWK to determine if neutrophil HMWK was HMWK derived from plasma bound to this cell's surface. The competitive inhibition curves (Fig. 2) Subsequent investigations determined the divalent cation requirements for binding of '25I-HMWK to neutrophils (Fig.  4) . As Zn2+ is an absolute divalent cation requirement for the binding of '25I-HMWK to platelets (16) binding of '251-HMWK to neutrophils (Fig. 4) . Therefore, Zn2+ was the only divalent cation tested required for binding of 121 I-HMWK to neutrophils.
Specificity of binding of '25I-HMWK binding to neutrophils. To ascertain whether the binding of '25I-HMWK to neutrophils was specific, we first investigated the capacity of other proteins, besides unlabeled HMWK, to inhibit binding of 125i-HMWK to neutrophils (Table I) . '251-HMWK binding to neutrophils was not inhibited by a 50-100-fold molar excess of Factor V, Factor XII or PK, and only modestly by FNDPs.
Further studies were performed to insure that the interaction of HMWK with neutrophils was not influenced by the radioiodination of HMWK. Washed neutrophils were incu- HMWK (6.5 nM) to neutrophils with a 50% inhibitory concentration of 32±16 nM. Using this mean 50% inhibitory concentration from these experiments, the apparent Ki was calculated to be about 9.6 nM using the formula of Mueller (27) (Fig. 7 B) . (Fig. 8) . When a 50-fold molar excess of unlabeled HMWK was added to the binding reaction at 8 and 18 min, rapid dissociation ofthe bound ligand occurred. At 8 min 96% ofthe bound ligand was displaced within I min, and at 18 min 93% of the bound ligand was displaced.
Because binding of '25I-HMWK to neutrophils was specific and reversible, studies were performed under equilibrium conditions to determine if binding was saturable. The number and affinity of '25I-HMWK binding sites on neutrophils were determined as a function of '25I-HMWK concentration. Increasing concentrations of '25I-HMWK were added to neutrophils in the absence or presence of a 50-fold molar excess of unlabeled ligand (Fig. 9 ). This figure is one representative experiment of three. As the concentration of added '251-HMWK increased, the level of binding increased until it leveled off at -3.5 ,ug/ml (29 nM) of the added 1251-HMWK (Fig. 9, left) . Using the graphical method of Scatchard (30), a saturable binding site was characterized to be one of the high affinity with an apparent Kd of 9 nM and 40,000 sites per cell (Fig. 9,  right) . This value from one experiment is similar to two other experiments, which together had a mean apparent Kd of this interpretation ofthe graphical representation ofthe experimental data was obtained by computer analysis of the same experimental data (31, 32) . Using a one site model for calculating the data for three experiments, a high affinity binding site with an apparent Kd of 18.0±2.6 nM (mean±SD) and 70,000±25,000 molecules per cell (mean±SD) was described. Role ofHMWK in HNE secretion in plasma. Further studies were performed to determine if HMWK has a role in HNE secretion. 10,000,000 normal human neutrophils were resuspended and preincubated for either 30 s or 30 min in normal plasma followed by recalcification for 60 min. Normal neutrophils released 1.08 ,g/ml HNE after 30 s and 0.7 ,ug/ml HNE, respectively after 30 min preincubation (Fig. 10, bar A) . In four separate experiments, normal neutrophils resuspended in total kininogen-deficient plasma released virtually identical amounts of HNE when compared with the same neutrophils resuspended in normal plasma after 30 s preincubation (data not shown). In contrast, the extent of HNE secretion from HMWK-deficient neutrophils suspended in total kininogendeficient plasma was 0.4 gg/ml HNE when preincubated for 30 s and 0.43 ,g/ml HNE for 30 min. (Fig. 10, bar B) . The release of HNE from HMWK-deficient neutrophils suspended in normal plasma was 0.42 gg/ml HNE when preincubated for 30 s but became normal, 0.98 ,g/ml HNE, when preincubated for 30 min. (Fig. 10, bar C) . These results suggest that HMWK bound to the neutrophil surface from plasma could contribute to HNE secretion and that neutrophil HMWK could also serve the same function.
Role of HMWK in neutrophil activation in a plasma-free system. Normal neutrophils stimulated with purified human plasma kallikrein (0.2 U/ml) released 16.6±8% of the total HNE and induced an initial rate of aggregation that was 36% of that which was induced by FMLP (0.2 ,uM). Alternatively, HMWK-deficient neutrophils stimulated with human PK (0.2 U/ml) released only 2.5% of the total HNE and induced an initial rate of aggregation that was 8% of that which was induced by FMLP (0.2 ,gM) (Table II) . These results confirm the importance of neutrophil HMWK in the absence of plasma HMWK.
Discussion
The demonstration that HMWK specifically binds to the surface of human neutrophils suggests that neutrophils contain unoccupied sites for the expression ofHMWK. The amount of '251-HMWK that binds to neutrophils is equivalent at 0, 23, and 370C, and remains constant over a 50-min incubation period (Fig. 3) . In addition, the binding of 125I-HMWK is completely reversible (Fig. 8) . Both of these studies suggest that the HMWK associated with neutrophil lysates (Fig. 1) Demonstration that '25I-HMWK binds to the surface of neutrophils indicates a means whereby HMWK from either plasma or neutrophils might be placed in a position such that it could influence the interaction of kallikrein with neutrophils.
The specificity of binding of 1251I-HMWK to neutrophils is shown using various approaches. Radiolabeled HMWK competes with equal affinity with unlabeled HMWK for neutrophil binding (Fig. 5 ) and excess unlabeled HMWK completely inhibits binding of '251-HMWK to neutrophils (Fig. 6) . In addition, only unlabeled HMWK, not Factor V, Factor XII, PK or FNDPs is able to prevent the binding of 125I-HMWK to the surface of the neutrophil (Table I) .
Although 1251-HMWK can bind to neutrophils in an intact form, neutrophil-bound '25I-HMWK undergoes proteolysis (Fig. 7) (Fig. 4) (Fig. 8) . The binding is characterized by one high-affinity, saturable site with an apparent Kd of 18.0±1.5 nM by computer fitting of the experimental points from three experiments (Fig. 9) . The estimated Ki computed from the midpoints of the competition inhibition curves from three experiments (Fig. 6) (27) is found to be similar at 10.4±4.0 nM.
Our studies (Fig. 2) show that unstimulated neutrophils do not have detectable HMWK on their surfaces. The functional significance of binding of HMWK to neutrophils is not yet fully delineated. Other peptides and proteins that bind to the neutrophil surface elicit responses from the neutrophil resulting in chemotaxis, aggregation, degranulation, and the respiratory burst. Kallikrein has been shown to result in neutrophil chemotaxis (4), aggregation (5) and degranulation (6) . Because prekallikrein circulates in plasma complexed with HMWK (2, 3), the ability of kallikrein to interact with neutrophils may result from the binding ofthe enzyme to the neutrophil surface in the presence ofHMWK. The inability of(f-kallikrein, which contains an additional cleavage in the heavy chain, to cause neutrophil activation (38) and the imparied cleavage of HMWK by ,B-kallikrein are consistent with this possibility since the heavy chain of kallikrein contains the binding region for HMWK (39) .
HMWK from either plasma or neutrophils appears to be a cofactor for HNE secretion from neutrophils (Fig. 10) . The finding that HMWK-deficient neutrophils suspended in total kininogen-deficient plasma had a reduced level of HNE secretion at 30 s and 30 min indicates a specific function of neutrophil HMWK in the mechanism of HNE secretion. Our previous studies (8) show that plasma kallikrein plays a role in the secretion of HNE. Because the release of HNE by purified kallikrein from HMWK-deficient neutrophils is only 15% compared with normal neutrophils (Table II) , we suggest that HMWK may serve as an acquired receptor for plasma kallikrein.
Our studies also demonstrate that HMWK is proteolyzed after binding to the surface of neutrophils. The proteolysis of HMWK by HNE may regulate the extent ofthe association of HMWK with neutrophils. Proteolysis of a bound ligand to neutrophils is not unique to HMWK. Cationic proteins identified as enzymes from the primary granules impair the che- 
